Key result
Beta-blocker use in older adults with incident congestive heart failure was associated with reduced all-cause mortality (HR 0.58; 95% CI 0.54-0.64), with consistent benefits regardless of CKD severity.
Why the study?
Does beta-blocker use reduce all-cause mortality in elderly patients with incident congestive heart failure and chronic kidney disease?
Does beta-blocker use reduce all-cause mortality in elderly patients with incident congestive heart failure and chronic kidney disease?
Hazard Ratio: 0.58 (95% CI 0.54–0.64)
Absolute Event Rate: 16% vs 24%
Number Needed to Treat: 17.3
No takes yet. Share an insight, caveat, or question.
This editorial highlights observational evidence that beta-blockers may reduce all-cause mortality in elderly patients with incident heart failure regardless of CKD severity, emphasizing the urgent need for randomized controlled trials in patients with severe CKD.
Agarwal et al. (2019) conducted an editorial in Incident congestive heart failure and chronic kidney disease (n=320,703). Beta-blockers vs. Nonusers of beta-blockers was evaluated on All-cause mortality (HR 0.58, 95% CI 0.54-0.64). Beta-blocker use in older adults with incident congestive heart failure was associated with reduced all-cause mortality (HR 0.58; 95% CI 0.54-0.64), with consistent benefits regardless of CKD severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: